Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma.

Cerciello, Ferdinando; Choi, Meena; Sinicropi-Yao, Sara L; Lomeo, Katie; Amann, Joseph M; Felley-Bosco, Emanuela; Stahel, Rolf A; Robinson, Bruce W S; Creaney, Jenette; Pass, Harvey I; Vitek, Olga; Carbone, David P (2020). Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma. Cancer epidemiology, biomarkers & prevention, 29(10), pp. 1973-1982. American Association for Cancer Research AACR 10.1158/1055-9965.EPI-20-0543

[img] Text
cerciello_cebp2020.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (817kB) | Request a copy


We have verified a mass spectrometry (MS)-based targeted proteomics signature for the detection of malignant pleural mesothelioma (MPM) from the blood.


A seven-peptide biomarker MPM signature by targeted proteomics in serum was identified in a previous independent study. Here, we have verified the predictive accuracy of a reduced version of that signature, now composed of six-peptide biomarkers. We have applied liquid chromatography-selected reaction monitoring (LC-SRM), also known as multiple-reaction monitoring (MRM), for the investigation of 402 serum samples from 213 patients with MPM and 189 cancer-free asbestos-exposed donors from the United States, Australia, and Europe.


Each of the biomarkers composing the signature was independently informative, with no apparent functional or physical relation to each other. The multiplexing possibility offered by MS proteomics allowed their integration into a single signature with a higher discriminating capacity than that of the single biomarkers alone. The strategy allowed in this way to increase their potential utility for clinical decisions. The signature discriminated patients with MPM and asbestos-exposed donors with AUC of 0.738. For early-stage MPM, AUC was 0.765. This signature was also prognostic, and Kaplan-Meier analysis showed a significant difference between high- and low-risk groups with an HR of 1.659 (95% CI, 1.075-2.562; P = 0.021).


Targeted proteomics allowed the development of a multianalyte signature with diagnostic and prognostic potential for MPM from the blood.


The proteomic signature represents an additional diagnostic approach for informing clinical decisions for patients at risk for MPM.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Cerciello, Ferdinando


600 Technology > 610 Medicine & health




American Association for Cancer Research AACR




Rebeka Gerber

Date Deposited:

08 Feb 2021 09:56

Last Modified:

08 Feb 2021 09:56

Publisher DOI:


PubMed ID:





Actions (login required)

Edit item Edit item
Provide Feedback